116 related articles for article (PubMed ID: 6843786)
1. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
Juorio AV
Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
[TBL] [Abstract][Full Text] [Related]
2. The effect of some precursor amino acids and enzyme inhibitors on the mouse striatal concentration of tyramines and homovanillic acid.
Juorio AV; Boulton AA
J Neurochem; 1982 Sep; 39(3):859-63. PubMed ID: 7097290
[TBL] [Abstract][Full Text] [Related]
3. Systemic and in vitro effects of GAD and GABA-T inhibitors on AADC activity and of AADC inhibitors on GAD.
Giorgi O; Rubio MC
Gen Pharmacol; 1981; 12(4):217-23. PubMed ID: 7250670
[No Abstract] [Full Text] [Related]
4. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat.
Treseder SA; Rose S; Summo L; Jenner P
J Neural Transm (Vienna); 2003 Mar; 110(3):229-38. PubMed ID: 12658372
[TBL] [Abstract][Full Text] [Related]
5. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
Polleri A; Masturzo P; Murialdo G; Carolei A
Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
[TBL] [Abstract][Full Text] [Related]
6. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
7. Cerebral decarboxylation of meta- and para-tyrosine.
Boulton AA; Juorio AV
Experientia; 1983 Feb; 39(2):130-4. PubMed ID: 6832285
[TBL] [Abstract][Full Text] [Related]
8. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
Yoshimine N; Kuzuya F; Mori K; Sakamoto N
Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
[No Abstract] [Full Text] [Related]
9. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
Drugs; 1976; 11(5):329-77. PubMed ID: 782834
[No Abstract] [Full Text] [Related]
10. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
Magnussen I; Van Woert MH
Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
[TBL] [Abstract][Full Text] [Related]
11. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
Minsker DH; Stokes AL
Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
[No Abstract] [Full Text] [Related]
12. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of Parkinson's disease: basic aspects and recent advances.
Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
[TBL] [Abstract][Full Text] [Related]
14. Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
Messiha FS
Proc West Pharmacol Soc; 1977; 20():327-31. PubMed ID: 896840
[No Abstract] [Full Text] [Related]
15. Decarboxylation of DL-2,4-dihydroxyphenylalanine (2,4-DOPA) to 2,4-dihydroxyphenylethylamine in mouse striatal slices.
Orosz D; Cohen G
Eur J Pharmacol; 1987 Apr; 136(3):441-4. PubMed ID: 3111867
[TBL] [Abstract][Full Text] [Related]
16. The effect of gamma-hydroxybutyrate on mouse striatal tyramine, dopamine and homovanillic acid.
Juorio AV
Br J Pharmacol; 1982 Mar; 75(3):447-50. PubMed ID: 7066598
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tyrosine-3-monooxygenase by benserazide.
Reinhard JF; Shearin MD
Biochem Pharmacol; 1990 May; 39(9):1489-91. PubMed ID: 1970732
[No Abstract] [Full Text] [Related]
18. Drug-induced changes in the formation, storage and metabolism of tyramine in the mouse.
Juorio AV
Br J Pharmacol; 1979 Jul; 66(3):377-84. PubMed ID: 43172
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine.
Dyck LE; Dewar KM
J Neurochem; 1986 Jun; 46(6):1899-903. PubMed ID: 2871132
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Goodale DB; Moore KE
Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
